Efficacy and Safety of Allergen-Specific Immunotherapy and Biologic Agents in Respiratory Allergies: A Literature Review
This literature review of studies from 2014 to 2024 concludes that both allergen-specific immunotherapy and biologic agents are effective and safe options for managing respiratory allergies, with treatment selection depending on individual patient characteristics and disease severity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human immune system as a vigilant security force, constantly scanning for invaders like bacteria and viruses. In most people, this force knows the difference between a genuine threat and harmless dust or pollen. But in those with allergies, the system misidentifies these innocent particles as dangerous enemies. This mistake triggers a chain reaction: the body produces a specific type of antibody called IgE, which acts like a warning signal. When the person encounters the allergen again, this signal alerts special cells to release a flood of chemicals, such as histamine, causing the familiar symptoms of sneezing, itchy eyes, and difficulty breathing. For decades, doctors have treated these reactions by simply blocking the chemicals or avoiding the triggers. However, a more fundamental approach has emerged: teaching the immune system to stop reacting in the first place. This is the goal of two modern strategies that researchers have recently examined in depth: allergen-specific immunotherapy, which gradually exposes the body to the allergen to build tolerance, and biologic agents, which are laboratory-made drugs designed to block specific parts of the immune response.
A team of researchers from Centro Universitário Unifaminas in Brazil set out to understand how well these two approaches work and how safe they are for people suffering from respiratory allergies like asthma and allergic rhinitis. They did not conduct new experiments on patients; instead, they gathered and analyzed sixty-five existing studies published between 2014 and 2024. Their goal was to piece together a clear picture of the current medical landscape, looking at how these treatments affect symptoms, quality of life, and the risk of side effects. By reviewing this wide range of data, they aimed to help doctors and patients decide which path might be best for different types of allergic conditions.
The researchers found that both strategies offer real benefits, but they work in distinct ways and suit different situations. Allergen-specific immunotherapy acts like a long-term training program for the immune system. It involves giving the patient small, increasing doses of the substance that causes the allergy, such as pollen or dust mites. This can be done through injections under the skin or by placing drops or tablets under the tongue. The studies showed that this method is highly effective at reducing symptoms of rhinitis and asthma over time. Patients often needed less medication to manage their condition, and their quality of life improved significantly. The treatment appeared to change the immune system's behavior, increasing levels of protective antibodies while lowering the markers of inflammation. One of the most encouraging findings was that these benefits often lasted for years, sometimes even after the treatment stopped. The safety profile was generally good, with most side effects being mild, such as itching in the mouth for those using tablets or local swelling for those receiving injections. Serious reactions were rare, occurring in a small fraction of patients, but they did happen, requiring careful monitoring.
On the other side of the comparison are biologic agents, which are powerful, targeted drugs used primarily for severe cases that do not respond well to standard treatments. These medications are designed to block specific molecules that drive the allergic inflammation. The review highlighted several of these drugs, including dupilumab, mepolizumab, and omalizumab. Dupilumab, for instance, works by blocking the signals that cause inflammation in conditions like chronic sinusitis with nasal polyps. The data showed it could dramatically improve breathing, sense of smell, and overall well-being, while also reducing the need for other strong medications like steroids. Mepolizumab targets a different pathway, focusing on a type of white blood cell called an eosinophil that is often high in severe asthma. Omalizumab works by neutralizing the IgE antibody itself. These drugs acted quickly and effectively in the severe cases studied, often bringing relief where other treatments had failed. Their side effects were generally mild, with the most common complaints being temporary pain or redness at the injection site. Unlike immunotherapy, which aims to retrain the immune system for the long term, these biologics act as a precise shield against the specific chemical pathways causing the trouble.
The researchers concluded that neither approach is a one-size-fits-all solution. The choice between them depends heavily on the individual patient, the severity of their disease, and their specific immune profile. For many people with moderate allergies, immunotherapy offers a path to long-term control and a potential cure by changing how the body reacts to allergens. For those with severe, complex, or refractory conditions, biologic agents provide a powerful tool to manage symptoms and prevent severe attacks. The review emphasized that the decision should be made carefully, weighing the long-term potential of immunotherapy against the rapid, targeted relief of biologics. While both methods have proven their worth, the study also noted that more research is needed to identify exactly which patients will respond best to which treatment and to explore how these therapies might be used together. Ultimately, the work confirms that modern medicine now has two distinct, effective tools to help people breathe easier and live better with respiratory allergies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.